Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tenosynovial Giant Cell Tumor: full-pipeline trial registry
3 of 9 indexed Tenosynovial Giant Cell Tumor trials are currently recruiting.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Tenosynovial Giant Cell Tumor: 9 US clinical trials tracked, 3 recruiting.
Tenosynovial Giant Cell Tumor is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Deciphera Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition tenosynovial-giant-cell-tumor
OPEN 3 | RECR 33% | LATE 3 | EARLY 4 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Tenosynovial Giant Cell Tumor lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tenosynovial Giant Cell Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tenosynovial Giant Cell Tumor is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tenosynovial Giant Cell Tumor research.
Deciphera Pharmaceuticals accounts for 3 of 9 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Tenosynovial Giant Cell Tumor enrolment sits around 100 participants.
Median target enrolment is 100 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Tenosynovial Giant Cell Tumor research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co
NCT04192344
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Deciphera Pharmaceuticals
NCT07075471
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Daiichi Sankyo
NCT04635111
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals
NCT05059262
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals
NCT03069469
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Abbisko Therapeutics Co
NCT05804045
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Daiichi Sankyo
NCT02371369
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Five Prime Therapeutics
NCT02471716
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Andrew J. Wagner, MD, PhD
NCT01207492
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Tenosynovial Giant Cell Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tenosynovial Giant Cell Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tenosynovial Giant Cell Tumor page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Tenosynovial Giant Cell Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Deciphera Pharmaceuticals sponsors the most Tenosynovial Giant Cell Tumor trials on record, review their full trial history before evaluating a specific study. See Deciphera Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tenosynovial Giant Cell Tumor condition card totals 9 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.